AERAS [to 28 May 2016]
http://www.aeras.org/pressreleases

.
May 23, 2016
Aeras Applauds Report and Recommendations by the Review on Antimicrobial Resistance
Aeras Applauds the Final Report and Recommendations by the United Kingdom Review on Antimicrobial Resistance

Rockville, MD,– Aeras applauds the Final Report and Recommendations released this week by the U.K. Review on Antimicrobial Resistance (Review) that highlights the extreme global health threat of antimicrobial resistance (AMR). The Review, led by economist Jim O’Neill, specifically notes the threat of multidrug-resistant tuberculosis (MDR-TB) and the imperative of increased global investment in research and development to save the millions of lives lost each year due to AMR related to tuberculosis (TB) and other infectious diseases.

The final report warns that if new therapies, diagnostics and a new vaccine are not introduced, MDR-TB will be responsible for 2.5 million deaths per year by 2050, or roughly one quarter of the forecasted 10 million deaths related to AMR – equating to one death due to MDR-TB every 12 seconds. An interim paper entitled Vaccines and Alternative Approaches: Reducing our Dependence on Antimicobials, published by the Review in February 2016, also emphasized the overwhelming need for new TB vaccines as an essential component of the global strategy to overcome TB and to address MDR-TB.

A key finding of the final report is that increased public and private investment in research and development will be essential to combatting AMR – saving millions of lives, as well as avoiding the serious economic impact of this global public health emergency…